Prem Chattoo and his team at Hudson River Gastroenterology are happy to address the most common questions they encounter regarding semaglutide and its effects on your digestive health
Retatrutide trials This page is for informational purposes only and does not constitute medical advice
Survodutide (BI 456906), developed by Boehringer Ingelheim and Zealand Pharma, has completed Phase 2 trials for obesity (18.7% weight loss at 46 weeks) and MASH (62% MASH resolution), earning FDA Breakthrough Therapy Designation for MASH
In addition to the role mentioned above in the process of oxidative stress, the GPX family also plays a unique role in tumor development (Strycharz-Dudziak et al., 2020), obesity (Rusetskaya et al., 2019), signal transduction, and inflammation (Rusetskaya et al., 2019)
Final word: Ignore the GLP-1 meds scaremongering and focus on the facts At the end of the day, this entire media firestorm is based on a handful of cases in people who were already at risk
While this approach can support sustainable weight management with fewer side effects, it remains off-label and lacks robust clinical data